Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
Open Access
- 18 January 2025
- journal article
- Published by Elsevier in Kidney International Reports
- Vol. 10 (4) , 1063-1075
Abstract
No abstract availableKeywords
Funding Information
- Kochi University
This publication has 36 references indexed in Scilit:
- Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatmentCEN Case Reports, 2024
- A multi-center randomized controlled trial to investigate potential effects of exercise therapy on renal function stratified by renal disorders and renal pathology: beneficial or harmful effect in immunoglobulin a nephropathyClinical and Experimental Nephrology, 2024
- Effects of a remote patient monitoring system for patients on automated peritoneal dialysis: a randomized crossover controlled trialInternational Urology and Nephrology, 2022
- Weight loss and cystic disease progression in autosomal dominant polycystic kidney diseaseiScience, 2021
- Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD)Clinical and Experimental Nephrology, 2021
- Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: a retrospective studyClinical and Experimental Nephrology, 2020
- Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney DiseaseCell Metabolism, 2019
- Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney diseaseKidney International, 2019
- Autosomal dominant polycystic kidney diseaseThe Lancet, 2019
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitorsKidney International, 2018